On 06 June 2022 the President of the Agency for Health Technology Assessment and Tariff System issued the following recommendation:
Recommendation No. 56/2022 of 6 June 2022 of the President of the Agency for Health Technology Assessment and Tariff System on the evaluation of Dupixent (dupilumab) under the drug programme: “Treatment of patients with severe atopic dermatitis (ICD-10 L20)” in children aged 6 to 11 years